174 results about "Lymphocytic cell" patented technology

Differential Methylation Hybridization (DMH) was used to identify novel methylation markers and methylation profiles for hematopoieetic malignancies, leukemia, lymphomas, etc. (e.g., non-Hodgkin's lymphomas (NHL), small B-cell lymphomas (SBCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL), chronic lymphocytic leukemia (CLL), multiple myeloma (MM), acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), etc.). Particular aspects provide novel biomarkers for NHL and subtypes thereof (e.g., MCL, B-CLL/SLL, FL, DLBCL, etc.), AML, ALL and MM, and further provide non-invasive tests (e.g. blood tests) for lymphomas and leukemias. Additional aspects provide markers for diagnosis, prognosis, monitoring responses to therapies, relapse, etc., and further provide targets and methods for therapeutic demethylating treatments. Further aspects provide cancer staging markers, and expression assays and approaches comprising idealized methylation and/or patterns” (IMP and/or IEP) and fusion of gene rankings.

The invention provides compositions and methods for determining a prognosis of a B cell chronic lymphocytic leukemia (CLL) in a subject based on the level of expression of at least one marker gene. Marker genes provided by the invention are SEPTlO, KIAA0799, Hs.23133, and ADAM29. The marker genes can be used to differentially diagnose CLL in a subject based on relative gene expression levels in the subject compared to reference gene expression levels established from a clinically characterized population of patients. The invention also provides diagnostic reagents and compositions and kits based on the marker genes.

The invention discloses chimeric antigen receptor T cells targeting CD19, and application of the chimeric antigen receptor T cells. A chimeric antigen receptor for preparing the chimeric antigen receptor T cells comprises interleukin 2 signal peptide, an anti-CD19 single chain antibody, a CD8 protein molecular hinge region, a transmembrane region, an intracellular signal structural domain, and anintracellular signal transduction structural domain of CD3 zeta protein molecules which are sequentially connected in series. The chimeric antigen receptor T cells are used for preparing medicines orpreparations for treating hematological malignancies, wherein the hematological malignancies comprise CD19-positive acute B-lymphocytic leukemia, diffuse large B-cell lymphoma and non-Hodgkin lymphoma.

The invention belongs to the technical field of blood products and particularly relates to a preparation method for platelet rich plasma (PRP). The method comprises a blood collection step, a lymphocyte separation medium treatment step, a first-time centrifugation step, a second-time centrifugation step and the like. According to the preparation method disclosed by the invention, on the basis of the existing PRP preparation technology, firstly, collected blood is treated by adopting a lymphocyte separation medium, and then, by optimizing a centrifugal force and time of centrifugation, the PRP concentration effect of the prepared PRP is further promoted, and the number of red blood cells is greatly reduced; the preparation method has better practical application value.

The invention aims to provide lactobacillus rhamnosus having bacteriostatic and immunity enhancement function, with the preservation number: CCTCC NO: M 2013355. The lactobacillus rhamnosus provided by the invention can be applied in the biological products which are medicines, food or health products. The lactobacillus rhamnosus has very powerful bacteriostatic ability, can obviously improve the achroacyte conversion and HCso of a mouse, phagocytosis rate and index of macrophage and NK cell activity, can enhance normal mouse immunity, and therefore can be widely applied in the medicines, food or the health products.

The present disclosure is directed, among other things, to automated systems and methods for analyzing, storing, and/or retrieving information associated with biological objects including lymphocytes. In some embodiments, a shape metric is derived for each detected and segmented lymphocyte and the shape metric is stored along with other relevant data.

The present invention provides a BTK inhibitor compound (having s structure represented by a formula (I)) and uses of the BTK inhibitor compound in medicines. According to the present invention, the compound and the pharmaceutical composition can be used for treatment of diffuse large B-cell lymphoma, follicular lymphoma or chronic lymphocytic leukemia. The formula (I) is defined in the specification.

The invention discloses a children acute lymphoblastic leukaemia genotyping diagnosis chip. The children acute lymphoblastic leukaemia genotyping diagnosis chip is a DNA chip which is fixed with 62 DNA fragment arrays on the surface of a carrier. .The nucleotide sequences of the 62 DNA fragment arrays are respectively the sequence 1 to the sequence 62 of the sequence list. The invention further discloses a children acute lymphoblastic leukaemia genotyping method. The genetic chip of the invention can provide precise typing so as to help correctly choose a chemo-treatment plan of appropriate strength, thereby reducing complicating disease and improving curative ratio and life quality. The genetic chip of the invention can be used to carry out genotyping on childhood ALL. Therefore, the genetic chip not only saves diagnosis cost, but also has significance in protecting labour resource and promoting family and society harmony.

The invention provides a Hyriopsis cumingii enzymolysis polypeptide, preparation and application thereof. The enzymolysis method comprises the following steps that: fresh Hyriopsis cumingii meat is crushed and pulped, and added with water of which the weight is 5 to 6 times of that of the fresh Hyriopsis cumingii meat; the mixture is boiled and filtered; the precipitate is dried and degreased to obtain albumen powder of the Hyriopsis cumingii meat; the albumen powder of the Hyriopsis cumingii meat is soaked in water of which the weight is 6 to 8 times of that of the albumen powder of the Hyriopsis cumingii meat for 11 to 12 hours and subjected to superfine grinding and even pulping, and the pH value of the mixed solution is adjusted to between 8.0 and 9.0; based on the albumen content in the albumen powder of the Hyriopsis cumingii meat, 0.3 to 0.6 percent of alkali protease is added in the mixed solution for enzymolysis for 4 to 6 hours at a temperature of between 40 and 60 DEG C; the obtained supernatant is condensed and dried to obtain the Hyriopsis cumingii enzymolysis polypeptide; and by testing, the content of the total albumen of the Hyriopsis cumingii enzymolysis polypeptide is more than or equal to 80 percent, wherein the contents of asparagic acid, glutamic acid, leucine, lysine and arginine are more than or equal to 50 percent, and the molecular weight is mainly concentrated in two zones of 6,100Da and 26,200Da. By a test for culturing mouse lymphocytes in vitro, the Hyriopsis cumingii enzymolysis polypeptide can be used for preparing a medicament for promoting proliferation of the T lymphocute and a health care food for improving the immunity.

The invention discloses a lymphocyte population with memory stem T cells as a main component and an in-vitro efficient amplification method of the lymphocyte population. The method comprises the steps as follows: peripheral blood mononuclear cells from healthy individuals are transferred into a culture flask precoated with anti-CD3 mAb, anti-CD28McAb and Novonectin, a serum-free medium containing IL-1alpha and IFN-gamma is added, a combination of multiple cytokines including VC, NAC, RAPA, IL-7, IL-15 and IL-21 is added, and then the serum-free medium and the combination of the multiple cytokines are supplemented; and the lymphocyte population with the memory stem T cells as the main component can be obtained after culture for 12 to 16 days. The combined application of the cytokines can have synergistic effect on amplification of lymphocytes, the amplification times are increased, and the in-vitro killing property and survival time are increased obviously; the method has the advantages of high safety, low cost and the like.

The invention relates to medical therapy using an agonist of the retinoic acid receptor-related orphan receptor gamma (ROR gamma) and provides adoptive cellular therapies using an agonist of ROR gamma, populations of lymphocyte cells that have been exposed to an agonist of ROR gamma, populations of dendritic cells that have been exposed to an agonist of ROR gamma, pharmaceutical compositions, and methods for enhancing therapeutic effects of lymphocyte cells and/or dendritic cells in a patient by administering an agonist of ROR gamma to a patient.

The invention relates to a lactobacillus rhamnosus strain 1.0320 with an immunomodulatory effect and application of the lactobacillus rhamnosus strain 1.0320. The lactobacillus rhamnosus strain 1.0320is applied to the fermentation process of yoghourt or pickles or used for preparing freeze-dried bacterial powder. According to the lactobacillus rhamnosus, the intestinal wall adhesion rate is high(up to 11.76% or above), the lactobacillus rhamnosus resists low pH (pH is lower than 3), and the lactobacillus rhamnosus resists bile salt (the colony count is 10<7> CFU/mL after the lactobacillus rhamnosus is incubated in 0.3% high-concentration bile salt for 4 hours). The lactobacillus rhamnosus 1.0320 (the ratio of lactobacillus to cells is 1: 1) has very strong regulation capability on a splenic lymphocyte transformation value and NO secreted by peritoneal macrophages, and the immunoregulation capability is obviously higher than that of a reference strain lactobacillus rhamnosus GG (p isless than 0.05). The immunoregulation intensity and concentration of the lactobacillus rhamnosus 1.0320 are positively correlated, when the ratio of lactobacillus rhamnosus 1.0320 to cells is 100: 1,the splenic lymphocyte transformation value is 7.5 times that of a positive control group, and the splenic lymphocyte proliferation index reaches 1 or above.

The invention provides a preparation for mobilizing mesenchymal stem cells and a method for separating the mesenchymal stem cells. The preparation for mobilizing the mesenchymal stem cells comprises CoCl2, wherein the CoCl2 is a hypoxia mimetic agent, and the dosage is in a range of 5-20mg/kg. The CoCl2 and AMD3100 are used in a combined manner. The dosage of the AMD3100 is 5mg/kg. According to the method for separating the mesenchymal stem cells by using the preparation, the preparation is used for actuating the mesenchymal stem cells to be mobilized, enter peripheral blood and then be separated. The method comprises the following separation steps of: sampling the periphery blood, separating mononuclear cells by using a lymphocyte separating medium, performing resuspension by using a DMEM (dulbeccos modified eagle medium) containing 20% of fetal bovine serum, inoculating to a culture flask, culturing for 7 days, and changing a culture solution, thus obtaining the mesenchymal stem cells of the peripheral blood on the 10th day. The mesenchymal stem cells of the peripheral blood highly express CD90, CD29 and CD44, do not express CD45 and CD34, and have the capacities of in vitro bone formation, fat formation and cartilage differentiation formation. The preparation is high in MSCs (mesenchymal stem cells) mobilization efficiency, and an effective preparation and an effective method are provided for tissue engineering and regenerative medicine.

The invention relates to antibodies that are reactive to the cell surface of CD19+ B cells, including B-cell chronic lymphocytic leukemia (B-CLL) cells, and compositions and methods for using such antibodies, including in the diagnosis and treatment of disorders associated with CD19+ B cells, such as B-CLL.

The present invention relates to a method for the treatment, amelioration or elimination of pediatric acute lymphoblastic leukemia (ALL), the method comprising the administration of a pharmaceutical composition comprising a CD19xCD3 bispecific single chain antibody construct to a pediatric ALL patient in the need thereof.

The invention relates to a method for in-vitro preparation of tumor antigen-specific CD8+ T memory stem cells and application of the tumor antigen-specific CD8+ T memory stem cells in antitumor immune response. The method comprises the following steps: subjecting tumor antigen and immature dendritic cells to co-incubation so as to obtain mature dendritic cells loaded with specific tumor antigen; subjecting the mature dendritic cells and CD8+ initial T cells to co-culture so as to promote generation of tumor antigen-specific CD8+ T memory stem cells; and separating out the CD8+ T memory stem cells capable of specifically recognizing specific tumor cells. The tumor antigen-specific CD8+ T memory stem cells prepared by using the method has good antineoplastic effect, high specificity and few adverse reaction.

The invention relates to the technical field of biological food, and provides exopolysaccharide produced by lactobacillus plantarum 589 in order to further protect the performance of lactobacillus plantarum 589, and the exopolysaccharide has the effect of promoting splenic lymphocyte proliferation. And the exopolysaccharide is obtained by culturing in an MRS liquid culture medium after activating.According to the invention, the performance of the lactobacillus plantarum 589 is deeply expanded, the exopolysaccharide produced by the lactobacillus plantarum 589 and the method for producing the exopolysaccharide at high yield are provided, and the yield of the exopolysaccharide reaches about 580mg/L; the lactobacillus plantarum 589 and derivatives thereof can promote proliferation of spleniclymphocytes; exopolysaccharide produced by the lactobacillus plantarum 589 has a low dosage concentration of only 1 [mu]g/mL for promoting splenic lymphocyte proliferation, and the lactobacillus plantarum 589 also has a low dosage concentration of only 1x10<7> CFU for promoting splenic lymphocyte proliferation.

The invention relates to methods of treating B-cell chronic lymphocytic leukemia, and other CD23⁺ malignancies, in patients with poor prognostic markers. The method comprises administration of an CD23 antibody, including for example, lumiliximab to a mammal that over expresses a poor prognostic marker. The method can also comprise administration of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab. Patients with poor prognostic markers include, for example, patients that overexpress ZAP70, CD38, β2-microglobulin and/or soluble CD23.